Therapeutic Group

Indication Dosage

Neovascular (wet) Age-related Macular Degeneration: 

By Intravitreal Inj: 

• Adult: 500 Mcg Once A Month, To Be Administered Into The Affected Eye, Monitor Visual Acuity Monthly, Continue Treatment Until Visual Acuity is Stable For 3 Consecutive Months, There after Monitor Visual Acuity Monthly, If Necessary Subsequent Doses May Be Given At Least 1 Month Apart; Discontinue Treatment If No Improvement In Visual Acuity After Initial 3 Injections 

Diabetic Macular Oedema, Macular Oedema Secondary To Retinal Vein Occlusion: 

By Intravitreal Inj: 

• Adult: Initially 500 Mcg Once A Month, To Be Administered Into The Affected Eye, Monitor Visual Acuity Monthly, Continue Treatment Until Visual Acuity is Stable For 3 Consecutive Months, There after Monitor Visual Acuity Monthly, If Necessary Subsequent Doses May Be Given At Least 1 Month Apart; Discontinue Treatment If No Improvement In Visual Acuity After Initial 3 Injections 

Choroidal Neovascularisation Secondary To Pathologic Myopia: 

By Intravitreal Inj: 

• Adult: Initially 500 Mcg, To Be Administered As A Single Injection Into The Affected Eye, Monitor For Disease Activity Monthly For the First 2 Months, Then At Least Every 3 Months Thereafter During The First Year, Then As Required, If Necessary Subsequent Doses May Be Given At Least 1 Month Apart 

Concomitant Treatment Of Diabetic Macular Oedema, Or Macular Oedema Secondary To Branch Retinal Vein Occlusion, With Laser Photocoagulation: 

By Intravitreal Inj: 

• Adult: 500 Mcg, To Be Administered At Least 30 Minutes After Laser Photocoagulation

Content

Pregnancy

Consult with Doctor Or Caution Advised

Stability

Contra Indications

Precautions

Lactation

Side Effects